Clinical Study of Anti-tumor Necrosis Factor Therapy in Patients With Takayasu Arteritis

Learn more about:
Related Clinical Trial
A Study of Ustekinumab in Participants With Takayasu Arteritis (TAK) Multicentre, Randomized, Prospective Trial Evaluating the Efficacy and Safety of Infliximab to Tocilizumab in Refractory or Relapsing Takayasu Arteritis A Pilot Study in Severe Patients With Takayasu Arteritis. Efficiency of Methotrexate and Tofacitinib in Mild and Moderate Patients Drug-coated Balloon for Takayasu Arteritis Associated Renal Artery Stenosis The Registry Study of Takayasu Arteritis in East China Fluorine F 18 Clofarabine PET/CT in Imaging Patients With Autoimmune or Inflammatory Diseases A Registry Study on Biomarkers of Takayasu’s Arteritis (ARSBTA) Infliximab Biosimilar in Takayasu’s Arteritis Exercise in Juvenile Takayasu Disease Pulmonary Artery Involvement in Takayasu’s Arteritis Anti-inflammatory Treatment for Inactive Takayasu Arteritis Efficacy and Tolerance of Tocilizumab In Takayasu Arteritis Aerobic Capacity and Strength Exercise in Takayasu’s Arteritis Use of MRI and PET for Assessing Disease Activity in Takayasu’s Arteritis Impact and Utility of PET Versus Clinical Score for the Assessment of Inflammatory Activity in Takayasu Arteritis Comparison of Mycophenolate Mofetil and Cyclophosphamide for Active Takayasu’s Arteritis Clinical Study of Anti-tumor Necrosis Factor Therapy in Patients With Takayasu Arteritis Registration Study of Takayasu’s Arteritis in China Determining Disease Activity Biomarkers in Individuals With Takayasu’s Arteritis Takayasu Arteritis Activity Evaluation by Ultrafast Ultrasound Imaging China Takayasu Arteritis Registry (CTA Registry) Takayasu Arteritis Clinical Trial in China

Brief Title

Clinical Study of Anti-tumor Necrosis Factor Therapy in Patients With Takayasu Arteritis

Official Title

Anti-tumor Necrosis Factor Therapy Effect on Takayasu Arteritis

Brief Summary

      Clinical study of anti-tumor necrosis factor therapy in patients with Takayasu arteritis.

      This study is single arm (anti Tumor necrosis factor therapy only) clinical trial. Enrolled
      patients will be 11
    

Detailed Description

      Clinical study of anti-tumor necrosis factor therapy in patients with Takayasu arteritis.

      This study is single arm (anti Tumor necrosis factor therapy only) clinical trial. Enrolled
      patients will be 11 patients with active takayasu's arteritis
    

Study Phase

Phase 2

Study Type

Interventional


Primary Outcome

remission induction at 30 weeks


Condition

Takayasu's Arteritis

Intervention

remicade (anti tumor necrosis factor inhibitor)

Study Arms / Comparison Groups

 experimental group
Description:  anti Tumor necrosis factor treatment group : treatment with remicade 5mg/kg as scheduled (0, 2, 6, 14, 22, 30, 38, 46, 54weeks).
evaluation of response at 30weeks by PET CT, acute phase reactants, symptom
No placebo group

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Drug

Estimated Enrollment

11

Start Date

March 2015

Completion Date

April 2018

Primary Completion Date

August 2017

Eligibility Criteria

        Inclusion Criteria:

          -  active takayasu's arteritis

        Exclusion Criteria:

          -  active Tuberculosis

          -  Liver function abnormality

          -  heart failure ( New York Heart Association III - IV)

          -  patients were not consented
      

Gender

All

Ages

18 Years - N/A

Accepts Healthy Volunteers

Accepts Healthy Volunteers

Contacts

Yeong Wook Song, MD,PhD, 82-10-8623-2648, [email protected]

Location Countries

Korea, Republic of

Location Countries

Korea, Republic of

Administrative Informations


NCT ID

NCT02457585

Organization ID

1312-079-541


Responsible Party

Sponsor

Study Sponsor

Seoul National University Hospital


Study Sponsor

Yeong Wook Song, MD,PhD, Principal Investigator, Seoul National University Hospital


Verification Date

March 2017